Are there any regadenoson generic applications in Europe right now?
I can’t answer that accurately with the information available here. To identify whether a specific “regadenoson” generic has an active Europe application (and where it is in the process), you need to check the European medicines databases directly—because registrations and procedural status change frequently.
A practical starting point is:
- European Medicines Agency (EMA) medicines pipeline/search tools and press releases.
- National competent authority listings (for the country you care about).
- The EU public assessment and authorisation records (when a generic receives marketing authorisation).
How to check whether a generic regadenoson has been filed, assessed, or approved in the EU
Search the EMA and EU systems using the exact INN (international non-proprietary name) “regadenoson” and filter by “generic” or the relevant status fields if available. Then confirm:
- Whether the product is “authorised” (marketing authorisation granted) versus only “under review”.
- The target member state(s) and the application route (centralised vs national vs mutual recognition—generic regimens often use national/mutual recognition routes).
- The legal basis used for generic approval (e.g., article/route depends on the specific situation and data package).
When would a generic regadenoson be expected to launch in Europe?
Generic availability in Europe depends on a mix of:
- Patent and supplementary protection certificate (SPC) status for the reference product (and any line-specific lifecycle protections).
- Regulatory exclusivities, if applicable.
- The administrative timeline after approval (label set-up, packaging, distribution).
If you share the reference brand name used in Europe (and the country you’re interested in), I can help you map what typically determines timing and which regulatory records you should look up first.
Is the issue patent/SPC protection rather than “application”?
It’s common for users to see “generic applications” discussed while actual market entry is delayed by:
- Patent/Sli protection still in force.
- Litigation or settlements that affect effective launch dates.
- SPC term differences across countries.
To assess this, you’d check:
- EP (European) patent families and any SPC registrations covering the relevant active ingredient/product.
- The authorised reference product and its listed protections for the specific EU member state(s).
Which countries are most likely to see regadenoson generics first?
In the EU, the first visible roll-out often depends on:
- Which company files first under national or mutual recognition.
- Which member state hosts the “reference” assessment.
- Local launch readiness and pricing/reimbursement timelines.
If you tell me the country (or countries) you care about, I can suggest the most relevant place to look (EMA vs national authority portal) and what product identifiers to use in searches.
What information should you include when asking “generic application”?
To get a precise answer, it helps to specify:
- The reference product/brand name (the European brand matters for patent/SPC and for which marketing authorisation the generic is linked to).
- The EU country (or “EU/EEA” broadly).
- Whether you mean “filed” (regulatory submission) or “approved” (marketing authorisation granted).
If you provide the brand name and the country, I can give a targeted checklist for what to verify and how to interpret the regulatory status you find.
---
Sources
None cited (your prompt didn’t include any provided source documents, and I don’t have access to live EU databases from this chat).